Stock SVE SYNTHAVERSE S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Synthaverse S.A.

Equities

SVE

PLBMDLB00018

Pharmaceuticals

Market Closed - Warsaw S.E.
Other stock markets
 09:25:54 10/05/2024 pm IST 		5-day change 1st Jan Change
4.94 PLN +2.70% Intraday chart for Synthaverse S.A. +2.92% +15.69%
10/04 Synthaverse S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Synthaverse S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 65.37 65.37 557.9 289.8 390.9 300
Enterprise Value (EV) 1 78 74.29 569.3 276.8 379 367.9
P/E ratio -1.94 x 26.3 x 128 x 66 x 66.6 x 63.1 x
Yield - - - - - -
Capitalization / Revenue 2.02 x 1.67 x 13.9 x 7.04 x 7.76 x 5.12 x
EV / Revenue 2.42 x 1.9 x 14.2 x 6.73 x 7.52 x 6.28 x
EV / EBITDA -36.7 x 6.79 x 50.9 x 23.1 x 23.7 x 24.6 x
EV / FCF -10.6 x 5.2 x -224 x -20.1 x -13.3 x -3.28 x
FCF Yield -9.45% 19.2% -0.45% -4.99% -7.5% -30.5%
Price to Book 2.15 x 1.96 x 15 x 3.8 x 3.99 x 2.66 x
Nbr of stocks (in thousands) 62,260 62,260 62,260 65,260 65,260 70,260
Reference price 2 1.050 1.050 8.960 4.440 5.990 4.270
Announcement Date 30/04/19 18/03/20 03/03/21 20/04/23 20/04/23 10/04/24
1PLN in Million2PLN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 32.29 39.11 40.16 41.15 50.38 58.61
EBITDA 1 -2.123 10.94 11.18 11.99 15.96 14.98
EBIT 1 -7.395 5.601 5.767 5.493 9.788 8.418
Operating Margin -22.9% 14.32% 14.36% 13.35% 19.43% 14.36%
Earnings before Tax (EBT) 1 -38.22 3.722 4.313 5.893 8.346 6.569
Net income 1 -32.41 2.483 4.439 4.249 6.081 4.758
Net margin -100.37% 6.35% 11.05% 10.32% 12.07% 8.12%
EPS 2 -0.5400 0.0399 0.0700 0.0673 0.0900 0.0677
Free Cash Flow 1 -7.368 14.3 -2.536 -13.8 -28.42 -112.1
FCF margin -22.82% 36.56% -6.32% -33.54% -56.41% -191.21%
FCF Conversion (EBITDA) - 130.76% - - - -
FCF Conversion (Net income) - 575.86% - - - -
Dividend per Share - - - - - -
Announcement Date 30/04/19 18/03/20 03/03/21 20/04/23 20/04/23 10/04/24
1PLN in Million2PLN
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 12.6 8.92 11.5 - - 67.9
Net Cash position 1 - - - 13 11.9 -
Leverage (Debt/EBITDA) -5.948 x 0.8153 x 1.025 x - - 4.531 x
Free Cash Flow 1 -7.37 14.3 -2.54 -13.8 -28.4 -112
ROE (net income / shareholders' equity) -73.5% 7.85% 12.7% 7.6% 6.75% 4.36%
ROA (Net income/ Total Assets) -4.46% 4.18% 4.32% 3.39% 4.37% 2.45%
Assets 1 726.8 59.36 102.8 125.4 139.1 194
Book Value Per Share 2 0.4900 0.5400 0.6000 1.170 1.500 1.600
Cash Flow per Share 2 0 0.0100 0.0300 0.2200 0.3900 0.0300
Capex 1 2.03 0.42 1.99 18.4 36.8 113
Capex / Sales 6.28% 1.08% 4.96% 44.78% 72.95% 192.13%
Announcement Date 30/04/19 18/03/20 03/03/21 20/04/23 20/04/23 10/04/24
1PLN in Million2PLN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
SYNTHAVERSE S.A. Stock Synthaverse S.A.
+15.69% 85.31M
CSL LIMITED Stock CSL Limited
-2.61% 88.47B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.55% 40.71B
BIOGEN INC. Stock Biogen Inc.
-13.99% 32.43B
UCB Stock UCB
+55.89% 24.28B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-15.87% 15.52B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-41.29% 12.17B
INCYTE CORPORATION Stock Incyte Corporation
-15.53% 12.01B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.75% 12B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+7.87% 8.87B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. SVE Stock
  4. Financials Synthaverse S.A.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW